ONCO

ONCO

NASDAQ

Onconetix, Inc.

1.94

-1.28(-39.75%)
Volume

68.8M

Market Cap

$6.65M

P/E Ratio

-1.82

EPS

$-4.28


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-1.82

P/B Ratio

1.62

EPS

$-4.28

ROE

-89.00%

Profit Margin

-1,720.98%

Operating Margin

-778.16%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
AZTR
Azitra, Inc.
$0.24 1.69% -0.11 $2.58M 0.16
ENVB
Enveric Biosciences, Inc.
$1.88 1.08% -0.06 $1.12M 0.00
INDP
Indaptus Therapeutics, Inc.
$1.78 0.00 -0.19 $3.12M 0.00
JSPR
Jasper Therapeutics, Inc.
$1.05 -5.41% -0.19 $17.07M 0.15
PTIX
Protagenic Therapeutics, Inc.
$0.52 -30.67% -0.20 $1.01M -1.32
REVB
Revelation Biosciences, Inc.
$1.13 0.00 -0.79 $1.67M 0.08
SCNI
Scinai Immunotherapeutics Ltd.
$0.60 0.00 -0.12 $790,536 0.30
SLRX
Salarius Pharmaceuticals, Inc.
$0.84 29.23% -0.61 $4.92M 0.00
SLXN
Silexion Therapeutics Ltd.
$1.22 -4.31% -0.32 $684,376 0.18
SPRC
SciSparc Ltd.
$3.91 -2.17% -0.02 $226,150 -3.14

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$14.88

52 Week Low

$0.44

Dividend

$0.12

Dividend Yield

1.60%

About Onconetix, Inc.

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.